For individuals living with treatment-resistant depression, finding an effective solution after multiple medication trials can feel discouraging. A certified Spravato® treatment center offers a structured, medically supervised approach designed specifically for adults who have not responded adequately to traditional antidepressants.
Spravato® (esketamine) is an FDA-approved nasal spray administered under clinical observation to ensure safety, monitoring, and optimal therapeutic outcomes. Unlike standard oral medications, it works on glutamate pathways in the brain, supporting rapid symptom relief for many patients. With comprehensive psychiatric evaluation, personalized dosing protocols, and ongoing care coordination, this specialized treatment for depression provides a clinically sound pathway toward meaningful and sustained improvement.
What Is a Spravato® Treatment Center and How Does It Work?
A Spravato® treatment facility is a certified medical facility authorized to administer esketamine (Spravato®) under the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program. These centers are specifically structured to treat adults with treatment-resistant depression (TRD) or major depressive disorder with suicidal ideation in a controlled, clinically supervised environment. Because Spravato® has unique safety and monitoring requirements, it cannot be dispensed for at-home use and must be administered onsite.
Below is how a Spravato® treatment clinic operates:
- Comprehensive Psychiatric Evaluation: A licensed provider conducts a detailed assessment to confirm diagnosis, review prior medication trials, evaluate medical history, and determine clinical eligibility.
- REMS Certification and Compliance: The facility and prescribing clinician are federally certified to administer Spravato® in accordance with strict safety protocols.
Supervised Nasal Administration: Spravato® is self-administered intranasally under direct medical supervision to ensure correct dosing technique. - Two-Hour Monitoring Period: Patients remain on-site for observation due to potential side effects, including dissociation, sedation, or transient blood pressure elevation.
- Vital Sign Monitoring: Blood pressure is assessed before and after dosing to reduce cardiovascular risk.
- Structured Induction and Maintenance Phases: Treatment begins with twice-weekly sessions (induction), followed by weekly or biweekly maintenance depending on response.
- Concurrent Oral Antidepressant: Spravato® is prescribed alongside an oral antidepressant as part of a combined treatment strategy.
- Ongoing Symptom Tracking: Clinicians measure mood changes, functional improvement, and side effects throughout treatment.
- Integrated Care Coordination: Therapy, medication management, and additional interventions may be incorporated to support long-term recovery.
This structured model ensures safety, regulatory compliance, and optimized clinical outcomes.
Who Is Eligible to Receive Treatment at a Spravato® Treatment Center?
Eligibility for treatment at a Spravato® treatment center is determined through a comprehensive psychiatric and medical evaluation. Spravato® is FDA-approved for adults diagnosed with treatment-resistant depression (TRD), meaning they have not achieved adequate symptom relief after trying at least two different antidepressant medications at appropriate doses and durations.
It is also approved, in combination with an oral antidepressant, for adults with major depressive disorder (MDD) who are experiencing acute suicidal thoughts or behaviors. A formal diagnosis and documented history of prior treatment attempts are essential components of the qualification process.
Candidates must be medically appropriate for treatment under supervised conditions. Because Spravato® can temporarily increase blood pressure and cause dissociation or sedation, providers carefully review cardiovascular health, neurological history, and any substance use concerns. Individuals with certain uncontrolled medical conditions, aneurysmal vascular disease, or a history of hypersensitivity to esketamine may not be eligible.
Additionally, patients must be willing and able to remain onsite for at least two hours after a Spravato® session for monitoring. They must arrange transportation home, as driving is not permitted on treatment days. Ultimately, eligibility is based on clinical necessity, safety considerations, and a provider’s determination that the potential benefits outweigh the risks.
Mental Health Treatment That Works
Call 949-625-0564What our customers are saying
What Should Patients Expect During a Spravato® Treatment Center Visit?
During a visit to a Spravato® treatment facility, patients can expect a structured, medically supervised process that prioritizes safety, comfort, and therapeutic effectiveness. Because Spravato® must be administered under FDA REMS guidelines, each appointment follows a consistent clinical protocol.
A typical visit includes:
- Pre-treatment assessment: Clinical staff review current symptoms, confirm medication compliance, and check vital signs, including blood pressure.
- On-site nasal administration: Patients self-administer the prescribed dose under direct supervision to ensure correct technique and adherence to dosing guidelines.
- Monitored observation period: Individuals remain in a comfortable treatment room for at least two hours while staff monitors for side effects such as dissociation, dizziness, nausea, or temporary sedation.
- Ongoing vital sign checks: Blood pressure and overall status are reassessed during and after the monitoring window.
- Clinical check-in before discharge: A provider evaluates stability and determines readiness to leave.
- Transportation requirement: Patients must arrange a ride home, as driving is not permitted until the following day after restful sleep.
Most patients describe the experience as calm and supportive, with staff available throughout the session. While some notice perceptual changes during treatment, these effects are typically transient. Regular follow-up appointments help track progress and adjust the treatment plan as needed for optimal outcomes.
How Do You Choose the Best Spravato® Treatment Center Near You?
Choosing the best Spravato® treatment clinic near you requires careful evaluation of clinical credentials, safety standards, the overall treatment model, and whether the clinic accepts insurance for Spravato® treatment. First, confirm that the facility and prescribing providers are certified under the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program.
REMS certification ensures the center meets strict federal guidelines for administering esketamine, including proper monitoring protocols and emergency preparedness. You should also verify that a licensed psychiatrist or qualified medical provider conducts comprehensive evaluations and oversees ongoing care.
Beyond certification, assess the center’s approach to integrated mental health treatment. Effective Spravato® programs do not operate in isolation. They combine medication management with therapy, symptom tracking, and individualized care planning.
Ask whether the center offers structured follow-up, outcome measurement, and coordination with your existing providers. Environment matters as well. Look for a setting that provides private, comfortable monitoring rooms and attentive clinical staff during the required two-hour observation period.
Finally, consider logistical factors such as scheduling flexibility, insurance verification support, and proximity to your home, since you will need reliable transportation after each session. A high-quality center prioritizes safety, transparency, and personalized care, helping ensure the treatment experience is both clinically sound and supportive of long-term recovery goals.
Key Takeaways on a Spravato® Treatment Center
- Spravato® Is Designed for Treatment-Resistant Depression: Spravato® (esketamine) is FDA-approved for adults with treatment-resistant depression and for certain individuals with major depressive disorder experiencing suicidal thoughts, offering an option when traditional antidepressants have not been effective.
- Treatment Must Be Administered in a Certified Setting: A Spravato® treatment clinic operates under the FDA’s REMS program, requiring onsite administration, strict safety protocols, and clinical supervision. The medication cannot be taken at home.
- Structured and Closely Monitored Process: Each visit includes a pre-treatment evaluation, supervised nasal administration, and a minimum two-hour monitoring period with vital sign checks to ensure patient safety.
- Comprehensive Eligibility Screening Is Required: Candidates must undergo psychiatric and medical evaluations to confirm the diagnosis, prior treatment history, and medical stability. Certain cardiovascular or neurological conditions may affect eligibility.
- Integrated, Ongoing Care Improves Outcomes: High-quality centers combine Spravato® with an oral antidepressant, symptom tracking, therapy, and coordinated follow-up care to support sustained improvement and long-term recovery.
If you or a loved one is struggling with treatment-resistant depression, specialized care may provide the breakthrough you have been seeking. At Moment of Clarity, our certified Spravato® treatment center delivers structured, medically supervised esketamine therapy in a safe and supportive outpatient setting. Our clinical team conducts comprehensive evaluations, personalized treatment planning, and ongoing progress monitoring to help you move toward lasting symptom relief. You do not have to continue cycling through ineffective medications without answers.
Contact Moment of Clarity today at 949-625-0564 to learn whether Spravato® is appropriate for your needs and begin your path toward meaningful recovery.
Resources
- Spravato® – IMPORTANT SAFETY INFORMATION
- Johnson & Johnson – Spravato® (esketamine)
- Johns Hopkins Medicine – Esketamine for Treatment-Resistant Depression
